Circadian rhythmicity in levodopa pharmacokinetics in patients with parkinson disease

Clinical Neuropharmacology

Volumn 33, Issue 4, 2010, Pages 181-185

  Nyholm, Dag ^a   Lennernäs, Hans ^b   Johansson, Anders ^a   Estrada, Matias ^a   Aquilonius, Sten Magnus ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

circadian rhythms; levodopa; nighttime; Parkinson disease; pharmacokinetics

Indexed keywords

BENSERAZIDE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; LEVODOPA;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BEDTIME DOSAGE; BODY POSITION; CIRCADIAN RHYTHM; CLINICAL ARTICLE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; FEMALE; HUMAN; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; STOMACH EMPTYING; SUPINE POSITION;

AGED; ANTIPARKINSON AGENTS; BIOLOGICAL AVAILABILITY; CIRCADIAN RHYTHM; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 77955143048     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181e70f7a     Document Type: Article

References (37)

1. Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 2004;19(9): 997-1005.
2. Nyholm D, Lennernas H, Gomes-Trolin C, et al. Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson's disease on individual drug combinations. Clin Neuropharmacol 2002;25(2):89-96.
3. Fabbrini G, Juncos J, Mouradian MM, et al. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol 1987;21(4):370-376. (Pubitemid 17053274)
4. Nyholm D, Lennernas H. Irregular gastrointestinal drug absorption in Parkinson's disease. Expert Opin Drug Metab Toxicol 2008;4(2): 193-203.
5. Nyholm D, Aquilonius SM. Levodopa infusion therapy in Parkinson disease: state of the art in 2004. Clin Neuropharmacol 2004;27(5):245-256.
6. Frankel JP, Pirtosek Z, Kempster PA, et al. Diurnal differences in response to oral levodopa. J Neurol Neurosurg Psychiatry 1990;53(11):948-950.
7. Monge A, Viselli F, Stocchi F, et al. Variation in the dopaminergic response during the day in Parkinson disease. Clin Neuropharmacol 2004;27(3):116-118.
8. Bonuccelli U, Del Dotto P, Lucetti C, et al. Diurnal motor variations to repeated doses of levodopa in Parkinson's disease. Clin Neuropharmacol 2000;23(1):28-33.
9. Bruguerolle B, Simon N. Biologic rhythms and Parkinson's disease: a chronopharmacologic approach to considering fluctuations in function. Clin Neuropharmacol 2002;25(4):194-201.
10. Baraldo M. The influence of circadian rhythms on the kinetics of drugs in humans. Expert Opin Drug Metab Toxicol 2008;4(2):175-192.
11. Arnulf I. Excessive daytime sleepiness in parkinsonism. Sleep Med Rev 2005;9(3):185-200.
12. Korczyn AD. Management of sleep problems in Parkinson's disease. J Neurol Sci 2006;248(1-2):163-166.
13. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009;8(5):464-474.
14. Merello M, Hughes A, Colosimo C, et al. Sleep benefit in Parkinson's disease. Mov Disord 1997;12(4):506-508.
15. Hogl BE, Gomez-Arevalo G, Garcia S, et al. A clinical, pharmacologic, and polysomnographic study of sleep benefit in Parkinson's disease. Neurology 1998;50(5):1332-1339.
16. Queckenberg C, Fuhr U. Influence ofposture on pharmacokinetics. Eur J Clin Pharmacol 2009;65(2):109-119.
17. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17(5):427-442.
18. Chaudhuri KR, Pal S, DiMarco A, et al. The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. J Neurol Neurosurg Psychiatry 2002;73(6): 629-635.
19. Andre MH, Grignon S, Bruguerolle B. Circadian phase dependent pharmacokinetics of L-dopa, its main metabolites (3-OMD, HVA, DOPAC) and carbidopa in rats. Fundam Clin Pharmacol 1996;10(4):350-355.
20. Nutt JG, Woodward WR, Carter JH, et al. Influence of fluctuations of plasma large neutral amino acids with normal diets on the clinical response to levodopa. J Neurol Neurosurg Psychiatry 1989;52(4): 481-487.
21. Oberle RL, Chen TS, Lloyd C, et al. The influence of the interdigestive migrating myoelectric complex on the gastric emptying of liquids. Gastroenterology 1990;99(5):1275-1282.
22. Chana P, Kuntsmann C, Reyes-Parada M, et al. Delayed early morning turn "on" in response to a single dose of levodopa in advanced Parkinson's disease: pharmacokinetics should be considered. J Neurol Neurosurg Psychiatry 2004;75(12):1782-1783.
23. Leeman AL, O'Neill CJ, Nicholson PW, et al. Parkinson's disease in the elderly: response to and optimal spacing of night time dosing with levodopa. Br J Clin Pharmacol 1987;24(5):637-643.
24. The UK Madopar CR Study Group. A comparison of Madopar CR and standard Madopar in the treatment of nocturnal and early-morning disability in Parkinson's disease. The U.K. Madopar CR Study Group. Clin Neuropharmacol 1989;12(6):498-505.
25. Schafer D, Greulich W. Effects of parkinsonian medication on sleep. J Neurol 2000;247(suppl 4):IV/24-27.
26. Hogl B, Rothdach A, Wetter TC, et al. The effect of cabergoline on sleep, periodic leg movements in sleep, and early morning motor function in patients with Parkinson's disease. Neuropsychopharmacology 2003;28(10):1866-1870.
27. Romigi A, Stanzione P, Marciani MG, et al. Effect ofcabergoline added to levodopa treatment on sleep-wake cycle in idiopathic Parkinson's disease: an open label 24-hour polysomnographic study. J Neural Transm 2006;113(12):1909- 1913.
28. Comella CL, Morrissey M, Janko K. Nocturnal activity with nighttime pergolide in Parkinson disease: a controlled study using actigraphy. Neurology 2005;64(8):1450-1451.
29. Gomez-Esteban JC, Zarranz JJ, Lezcano E, et al. Sleep complaints and their relation with drug treatment in patients suffering from Parkinson's disease. Mov Disord 2006;21(7):983-988.
30. Nyholm D, Jansson R, Willows T, et al. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements. Neurology 2005;65(9):1506-1507.
31. Sage JI, Mark MH. Nighttime levodopa infusions to treat motor fluctuations in advanced Parkinson's disease: preliminary observations. Ann Neurol 1991;30(4):616-617.
32. Vetrugno R, Contin M, Baruzzi A, et al. Polysomnographic and pharmacokinetic findings in levodopa-induced augmentation of restless legs syndrome. Mov Disord 2006;21(2):254-258.
33. Bordet R, Devos D, Brique S, et al. Study of circadian melatonin secretion pattern at different stages of Parkinson's disease. Clin Neuropharmacol 2003;26(2):65-72.
34. Hineno T, Mizobuchi M, Nishimatsu O, et al. Day-night variation of urine volume in Parkinson's disease. Jpn J Psychiatry Neurol 1994;48(3):583-587.
35. Gancher ST, Nutt JG. Diurnal responsiveness to apomorphine. Neurology 1987;37(7):1250-1253.
36. Sowers JR, Vlachakis N. Circadian variation in plasma dopamine levels in man. JEndocrinol Invest 1984;7(4):341-345.
37. Tandberg E, Larsen JP, Karlsen K. Excessive daytime sleepiness and sleep benefit in Parkinson's disease: a community-based study. Mov Disord 1999;14(6):922-927.